MCID: OVR012
MIFTS: 44

Ovarian Serous Cystadenocarcinoma malady

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Ovarian Serous Cystadenocarcinoma

Aliases & Descriptions for Ovarian Serous Cystadenocarcinoma:

Name: Ovarian Serous Cystadenocarcinoma 12 52 14 69
Cystadenoma, Serous 69
Serous Cystadenoma 12
Cystadenoma Serous 52

Classifications:



External Ids:

Disease Ontology 12 DOID:5746
NCIt 47 C7978
UMLS 69 C0279663

Summaries for Ovarian Serous Cystadenocarcinoma

Disease Ontology : 12 An ovary serous adenocarcinoma that has material basis in glandular epithelium, in which cystic accumulations of retained secretions are formed.

MalaCards based summary : Ovarian Serous Cystadenocarcinoma, also known as cystadenoma, serous, is related to pancreatic serous cystadenoma and cystadenoma. An important gene associated with Ovarian Serous Cystadenocarcinoma is ZNF217 (Zinc Finger Protein 217), and among its related pathways/superpathways are Glioma and Apoptosis Modulation and Signaling. The drugs Doxorubicin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include ovary and breast, and related phenotypes are cellular and endocrine/exocrine gland

Related Diseases for Ovarian Serous Cystadenocarcinoma

Diseases related to Ovarian Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 68)
id Related Disease Score Top Affiliating Genes
1 pancreatic serous cystadenoma 12.4
2 cystadenoma 10.8
3 pancreatitis 10.6
4 cystadenocarcinoma 10.5
5 serous cystadenocarcinoma 10.5
6 cervical serous adenocarcinoma 10.2 UBE4A USP2 ZNF217
7 deafness, autosomal recessive 21 10.2 ESR2 PGR
8 biemond syndrome 10.2 BCL2 PGR
9 her2-receptor negative breast cancer 10.2 ESR2 PGR
10 isolated anterior cervical hypertrichosis 10.1 HIF1A VEGFA
11 osteogenesis imperfecta 10.1 ESR2 PGR
12 adenoma 10.1
13 main bronchus cancer 10.1 PGR VEGFA
14 twin-to-twin transfusion syndrome 10.1 BAX BCL2
15 vaginal adenosarcoma 10.1 BCL2 BIRC5 PGR
16 trachea squamous cell carcinoma 10.1 AKT1 PGR VEGFA
17 malignant pleural solitary fibrous tumor 10.0 AKT1 PGR VEGFA
18 prostatic adenoma 10.0 ESR2 PGR VEGFA
19 cleft palate cardiac defect ectrodactyly 10.0 BCL2 HIF1A VEGFA
20 adult medulloblastoma 10.0 AKT1 ESR2 VEGFA
21 immune system disease 10.0 ESR2 PGR VEGFA
22 dental caries 10.0 AKT1 PGR VEGFA ZNF217
23 nasal cavity disease 10.0 AKT1 PGR VEGFA ZNF217
24 pyloric antrum cancer 10.0 BAX BCL2 VEGFA
25 nevoid hypermelanosis, linear and whorled 10.0 BCL2 BIRC5 VEGFA
26 kidney disease 9.9 BAX BCL2
27 microcystic adenoma 9.9
28 obstructive jaundice 9.9
29 adenocarcinoma 9.9
30 sarcomatoid renal cell carcinoma 9.9 BIRC5 HIF1A VEGFA
31 prostate cancer, hereditary, x-linked 1 9.9 AKT1 BAX ESR2
32 bardet-biedl syndrome 9.9 AKT1 ESR2 PGR VEGFA
33 sacrococcygeal teratoma 9.9 BAX HIF1A VEGFA
34 acute thyroiditis 9.9 ESR2 FSHR PGR
35 breast mucinous cystadenocarcinoma 9.9 FSHR UBE4A USP2 ZNF217
36 avoidant personality disorder 9.9 ESR2 FSHR PGR
37 portal hypertension 9.9
38 endosalpingiosis 9.9
39 struma ovarii 9.9
40 leydig cell tumor 9.9
41 sertoli-leydig cell tumor 9.9
42 tuberculosis 9.9
43 cystadenofibroma 9.9
44 leukemia 9.9
45 ovarian cancer 9.9
46 endometriosis 9.9
47 plasma cell leukemia 9.9
48 ovarian brenner tumor 9.9 AKT1 HIF1A VEGFA
49 glucosephosphate isomerase deficiency 9.8 BAX BCL2 VEGFA
50 thanatophoric dysplasia, type ii 9.8 BAX BIRC5 HIF1A

Graphical network of the top 20 diseases related to Ovarian Serous Cystadenocarcinoma:



Diseases related to Ovarian Serous Cystadenocarcinoma

Symptoms & Phenotypes for Ovarian Serous Cystadenocarcinoma

MGI Mouse Phenotypes related to Ovarian Serous Cystadenocarcinoma:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.24 AKT1 BAX BCL2 BIRC5 ESR2 FSHR
2 endocrine/exocrine gland MP:0005379 10.22 AKT1 BAX BCL2 BIRC5 ESR2 FSHR
3 behavior/neurological MP:0005386 10.21 AKT1 BAX BCL2 ESR2 FSHR HIF1A
4 hematopoietic system MP:0005397 10.21 HIF1A PGR USP2 VEGFA AKT1 BAX
5 homeostasis/metabolism MP:0005376 10.19 AKT1 BAX BCL2 BIRC5 ESR2 FSHR
6 cardiovascular system MP:0005385 10.15 AKT1 BCL2 ESR2 FSHR HIF1A PGR
7 immune system MP:0005387 10.13 AKT1 BAX BCL2 BIRC5 ESR2 FSHR
8 mortality/aging MP:0010768 10.06 AKT1 BAX BCL2 BIRC5 ESR2 FSHR
9 integument MP:0010771 10 AKT1 BCL2 ESR2 FSHR HIF1A PGR
10 neoplasm MP:0002006 9.92 AKT1 BAX BCL2 ESR2 FSHR HIF1A
11 limbs/digits/tail MP:0005371 9.91 BAX ESR2 FSHR HIF1A PGR VEGFA
12 muscle MP:0005369 9.91 AKT1 BAX BCL2 ESR2 HIF1A PGR
13 reproductive system MP:0005389 9.76 AKT1 BAX BCL2 ESR2 FSHR PGR
14 renal/urinary system MP:0005367 9.73 BAX BCL2 ESR2 HIF1A USP2 VEGFA
15 respiratory system MP:0005388 9.43 BAX BCL2 ESR2 AKT1 HIF1A VEGFA
16 skeleton MP:0005390 9.17 AKT1 BAX ESR2 FSHR HIF1A PGR

Drugs & Therapeutics for Ovarian Serous Cystadenocarcinoma

Drugs for Ovarian Serous Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
4
Ethanol Approved Phase 2, Phase 3,Phase 1 64-17-5 702
5
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
6
Topotecan Approved, Investigational Phase 2, Phase 3, Phase 1 119413-54-6, 123948-87-8 60700
7
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
8
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
9
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
10
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
11
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
12
Succinylcholine Approved Phase 3,Phase 2,Phase 1 306-40-1 5314
13
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
14
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
15
Olaparib Approved Phase 2, Phase 3,Phase 1 763113-22-0 23725625
16
Oxaliplatin Approved, Investigational Phase 3,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
17
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
18
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
20
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
21
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
22
Cediranib Investigational Phase 2, Phase 3,Phase 1 288383-20-0 9933475
23
Maleic acid Experimental Phase 2, Phase 3,Phase 1 110-16-7 444266
24 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
25 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
26 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
27 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
28 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
29 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
30 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
31 Antimitotic Agents Phase 3,Phase 2,Phase 1
32 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
33 Alkylating Agents Phase 3,Phase 2,Phase 1
34 topoisomerase I inhibitors Phase 2, Phase 3, Phase 1
35 Mitogens Phase 3,Phase 2,Phase 1
36 Selective Estrogen Receptor Modulators Phase 2, Phase 3
37 Hormone Antagonists Phase 2, Phase 3
38 Hormones Phase 2, Phase 3
39 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
40 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
41 Estrogen Receptor Modulators Phase 2, Phase 3
42 Estrogens Phase 2, Phase 3
43 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3,Phase 1
44 Immunoglobulin G Phase 3,Phase 2,Phase 1
45 Immunoglobulins Phase 3,Phase 2,Phase 1
46 Anti-Infective Agents Phase 2, Phase 3, Phase 1
47 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
48 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
49 Protein Kinase Inhibitors Phase 2, Phase 3, Phase 1
50 Anti-Infective Agents, Local Phase 2, Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 123)
id Name Status NCT ID Phase
1 Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy Unknown status NCT02097446 Phase 3
2 EUS-Guided Pancreatic Injection of Cyst (EPIC) Trial Completed NCT00233038 Phase 2, Phase 3
3 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3
4 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3
5 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3
6 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3
7 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3
8 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3
9 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
10 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3
11 Efficacy and Safety of Radiofrequency Ablation in Pancreatic Neuroendocrine and Cystic Tumor Recruiting NCT02330497 Phase 3
12 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Recruiting NCT02101788 Phase 2, Phase 3
13 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT00565851 Phase 3
14 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
15 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3
16 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3
17 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3
18 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3
19 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Active, not recruiting NCT01081262 Phase 3
20 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not yet recruiting NCT02839707 Phase 2, Phase 3
21 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3
22 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3
23 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
24 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2
25 Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Unknown status NCT00003560 Phase 2
26 Toremifene in Treating Patients With Ovarian Cancer Completed NCT00003865 Phase 2
27 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2
28 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2
29 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
30 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2
31 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer Completed NCT00008138 Phase 2
32 TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00022347 Phase 2
33 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00003944 Phase 2
34 Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2
35 Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers Completed NCT00002538 Phase 2
36 Phase II ABT-888 With Cyclophosphamide Completed NCT01306032 Phase 2
37 Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer Completed NCT01583322 Phase 2
38 AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00275028 Phase 2
39 Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer Completed NCT00664781 Phase 2
40 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT01210222 Phase 2
41 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Completed NCT01196429 Phase 2
42 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02101775 Phase 2
43 Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02122185 Phase 2
44 Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02853318 Phase 2
45 Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02345265 Phase 2
46 Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02713386 Phase 1, Phase 2
47 MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
48 Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02627443 Phase 1, Phase 2
49 MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Recruiting NCT02364713 Phase 2
50 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2

Search NIH Clinical Center for Ovarian Serous Cystadenocarcinoma

Genetic Tests for Ovarian Serous Cystadenocarcinoma

Anatomical Context for Ovarian Serous Cystadenocarcinoma

MalaCards organs/tissues related to Ovarian Serous Cystadenocarcinoma:

39
Ovary, Breast

Publications for Ovarian Serous Cystadenocarcinoma

Articles related to Ovarian Serous Cystadenocarcinoma:

(show all 18)
id Title Authors Year
1
Estimation of Prognostic Marker Genes by Public Microarray Data in Patients with Ovarian Serous Cystadenocarcinoma. ( 27189279 )
2016
2
DNA methylation-regulated microRNA pathways in ovarian serous cystadenocarcinoma: A meta-analysis. ( 27746113 )
2016
3
Single nucleotide polymorphisms in glutathione S-transferase P1 and M1 genes and overall survival of patients with ovarian serous cystadenocarcinoma treated with chemotherapy. ( 27073511 )
2016
4
A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma. ( 27478834 )
2016
5
Ovarian serous cystadenocarcinoma metastasising to the breast. ( 23445161 )
2013
6
Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. ( 21266826 )
2010
7
Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. ( 18574502 )
2008
8
[Differential expression of USP2, USP14 and UBE4A between ovarian serous cystadenocarcinoma and adjacent normal tissues]. ( 17553343 )
2007
9
Plasma cell leukemia with ovarian serous cystadenocarcinoma. ( 17883177 )
2007
10
[Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications]. ( 16793610 )
2006
11
[ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization]. ( 17160949 )
2006
12
Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. ( 11201519 )
2001
13
Immunohistochemical localization of aromatase and apoptosis-associated proteins in ovarian serous cystadenocarcinoma arising from ovarian endometriosis. ( 11516810 )
2001
14
Successful treatment of an advanced ovarian serous cystadenocarcinoma in pregnancy with cisplatin, adriamycin and cyclophosphamide (CAP) regimen. Case report. ( 10968352 )
2000
15
Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. ( 9506768 )
1998
16
Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen. ( 2314830 )
1990
17
Experiments with tissue cultures from a human ovarian serous cystadenocarcinoma producing cancer antigen 125 (CA125), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). ( 3165255 )
1988
18
Characterization of newly established cell line HUOA from a human ovarian serous cystadenocarcinoma. ( 3598277 )
1987

Variations for Ovarian Serous Cystadenocarcinoma

ClinVar genetic disease variations for Ovarian Serous Cystadenocarcinoma:

6 (show all 42)
id Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
2 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
3 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
4 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
5 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
6 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
7 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
8 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
9 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
10 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
11 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
12 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
13 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
14 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
15 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
16 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
17 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
18 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
19 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
20 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
21 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
22 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic/Likely pathogenic rs148924904 GRCh37 Chromosome 17, 7578442: 7578442
23 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
24 TP53 NM_000546.5(TP53): c.580C> T (p.Leu194Phe) single nucleotide variant Pathogenic/Likely pathogenic rs587780071 GRCh37 Chromosome 17, 7578269: 7578269
25 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
26 TP53 NM_000546.5(TP53): c.701A> G (p.Tyr234Cys) single nucleotide variant Pathogenic/Likely pathogenic rs587780073 GRCh37 Chromosome 17, 7577580: 7577580
27 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
28 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
29 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
30 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587782289 GRCh37 Chromosome 17, 7577575: 7577575
31 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
32 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic/Likely pathogenic rs786201059 GRCh37 Chromosome 17, 7577082: 7577082
33 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 GRCh38 Chromosome 17, 7673796: 7673796
34 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic/Likely pathogenic rs760043106 GRCh38 Chromosome 17, 7674947: 7674947
35 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
36 TP53 NM_000546.5(TP53): c.833C> T (p.Pro278Leu) single nucleotide variant Pathogenic/Likely pathogenic rs876659802 GRCh37 Chromosome 17, 7577105: 7577105
37 NRAS NM_002524.4(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
38 NRAS NM_002524.4(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs121913255 GRCh37 Chromosome 1, 115256528: 115256528
39 NRAS NM_002524.4(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
40 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
41 TP53 NM_000546.5(TP53): c.713G> T (p.Cys238Phe) single nucleotide variant Pathogenic/Likely pathogenic rs730882005 GRCh37 Chromosome 17, 7577568: 7577568
42 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 GRCh37 Chromosome 17, 7578407: 7578407

Expression for Ovarian Serous Cystadenocarcinoma

Search GEO for disease gene expression data for Ovarian Serous Cystadenocarcinoma.

Pathways for Ovarian Serous Cystadenocarcinoma

Pathways related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 47)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.88 AKT1 BAX BCL2 ESR2 PGR VEGFA
2
Show member pathways
12.7 AKT1 BAX BCL2 BIRC5
3
Show member pathways
12.7 AKT1 BAX BCL2 HIF1A VEGFA
4
Show member pathways
12.48 AKT1 BAX BCL2 BIRC5
5
Show member pathways
12.39 AKT1 BAX BCL2 ESR2
6 12.33 AKT1 BAX BCL2 BIRC5 HIF1A VEGFA
7
Show member pathways
12.27 AKT1 BAX BCL2 BIRC5
8
Show member pathways
12.18 AKT1 BAX BCL2 HIF1A
9 12.14 BAX BCL2 BIRC5
10 12.12 AKT1 BAX BCL2
11 12.09 AKT1 BAX BIRC5 VEGFA
12 12.08 ESR2 HIF1A VEGFA
13 12.05 AKT1 BAX BCL2 VEGFA
14 12.01 AKT1 BAX BCL2
15 11.99 AKT1 BCL2 VEGFA
16 11.95 AKT1 BCL2 HIF1A
17
Show member pathways
11.94 AKT1 BAX BCL2
18 11.94 AKT1 BAX BCL2 USP2
19
Show member pathways
11.93 AKT1 BAX BCL2
20 11.91 AKT1 BAX BCL2
21 11.89 AKT1 BAX BCL2
22
Show member pathways
11.79 AKT1 HIF1A VEGFA
23
Show member pathways
11.73 BAX BCL2 BIRC5
24 11.7 AKT1 BAX BCL2 VEGFA
25 11.66 AKT1 BCL2 HIF1A VEGFA
26 11.61 AKT1 HIF1A VEGFA
27 11.49 AKT1 BAX BCL2 BIRC5
28 11.44 AKT1 BAX BCL2
29 11.41 AKT1 BAX BCL2
30 11.4 AKT1 BCL2 BIRC5
31 11.35 AKT1 BCL2 BIRC5
32 11.22 AKT1 BAX BCL2
33 11.21 ESR2 FSHR PGR
34 11.16 AKT1 BIRC5 HIF1A VEGFA
35 11.12 AKT1 FSHR
36 11.12 BAX BCL2 ESR2
37 11.11 AKT1 ESR2
38 11.08 AKT1 BCL2 BIRC5 HIF1A VEGFA
39 11.05 AKT1 BCL2
40 11.03 AKT1 HIF1A VEGFA
41
Show member pathways
11.02 BAX BCL2
42 10.99 AKT1 BAX BCL2
43 10.95 BAX BCL2
45 10.82 BAX BIRC5 HIF1A VEGFA
46 10.64 BAX BCL2
47 10.58 HIF1A VEGFA

GO Terms for Ovarian Serous Cystadenocarcinoma

Cellular components related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.96 AKT1 BAX BCL2 BIRC5 ESR2 HIF1A
2 nucleoplasm GO:0005654 9.56 AKT1 BCL2 BIRC5 ESR2 HIF1A PGR
3 mitochondrial outer membrane GO:0005741 9.33 BAX BCL2 PGR
4 pore complex GO:0046930 8.62 BAX BCL2

Biological processes related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 31)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.88 AKT1 BCL2 BIRC5 HIF1A VEGFA
2 male gonad development GO:0008584 9.74 BAX BCL2 FSHR
3 kidney development GO:0001822 9.72 BAX BCL2 VEGFA
4 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.7 AKT1 BCL2 VEGFA
5 positive regulation of endothelial cell proliferation GO:0001938 9.67 AKT1 HIF1A VEGFA
6 dopaminergic neuron differentiation GO:0071542 9.65 HIF1A VEGFA
7 negative regulation of reactive oxygen species metabolic process GO:2000378 9.65 BCL2 HIF1A
8 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.64 AKT1 VEGFA
9 positive regulation of blood vessel endothelial cell migration GO:0043536 9.64 AKT1 VEGFA
10 negative regulation of ossification GO:0030279 9.63 BCL2 HIF1A
11 release of cytochrome c from mitochondria GO:0001836 9.63 BAX BCL2
12 positive regulation of neuroblast proliferation GO:0002052 9.62 HIF1A VEGFA
13 B cell homeostasis GO:0001782 9.62 BAX BCL2
14 negative regulation of neuron apoptotic process GO:0043524 9.62 BAX BCL2 BIRC5 HIF1A
15 camera-type eye morphogenesis GO:0048593 9.61 HIF1A VEGFA
16 positive regulation of nitric-oxide synthase activity GO:0051000 9.61 AKT1 HIF1A
17 negative regulation of apoptotic signaling pathway GO:2001234 9.6 BAX BCL2
18 digestive tract morphogenesis GO:0048546 9.59 BCL2 HIF1A
19 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.58 HIF1A VEGFA
20 endoplasmic reticulum calcium ion homeostasis GO:0032469 9.58 BAX BCL2
21 growth GO:0040007 9.56 BCL2 VEGFA
22 regulation of protein heterodimerization activity GO:0043497 9.54 BAX BCL2
23 ovarian follicle development GO:0001541 9.54 BAX BCL2 VEGFA
24 regulation of protein homodimerization activity GO:0043496 9.51 BAX BCL2
25 Sertoli cell proliferation GO:0060011 9.46 BAX FSHR
26 leukocyte homeostasis GO:0001776 9.43 BAX BCL2
27 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.4 HIF1A VEGFA
28 regulation of nitrogen utilization GO:0006808 9.26 BAX BCL2
29 positive regulation of developmental pigmentation GO:0048087 9.16 BAX BCL2
30 apoptotic mitochondrial changes GO:0008637 9.13 AKT1 BAX BCL2
31 cellular response to hypoxia GO:0071456 8.92 AKT1 BCL2 HIF1A VEGFA

Molecular functions related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.71 BAX BCL2 HIF1A VEGFA
2 steroid binding GO:0005496 9.43 ESR2 PGR
3 identical protein binding GO:0042802 9.43 AKT1 BAX BCL2 BIRC5 USP2 VEGFA
4 protein phosphatase 2A binding GO:0051721 9.37 AKT1 BCL2
5 channel activity GO:0015267 9.32 BAX BCL2
6 BH3 domain binding GO:0051434 9.16 BAX BCL2
7 enzyme binding GO:0019899 9.02 AKT1 BIRC5 ESR2 HIF1A PGR
8 protein binding GO:0005515 10.03 AKT1 BAX BCL2 BIRC5 ESR2 FSHR

Sources for Ovarian Serous Cystadenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....